{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:13:25Z","timestamp":1787062405908,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,5]]},"DOI":"10.7759\/cureus.75180","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T22:34:48Z","timestamp":1733438088000},"source":"Crossref","is-referenced-by-count":1,"title":["Urotoxicity of Cyclophosphamide: A Comparison Across Neoplastic, Autoimmune, and Transplant Indications"],"prefix":"10.7759","author":[{"given":"Joyce H","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Samarneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi A","year":"2009","unstructured":"Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009, 6:638-47. 10.1038\/nrclinonc.2009.146","journal-title":"Nat Rev Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-019-02589-1","article-title":"Novel insights into the mechanism of cyclophosphamide-induced bladder toxicity: chloroacetaldehyde's contribution to urothelial dysfunction in vitro","volume":"93","author":"Mills KA","year":"2019","unstructured":"Mills KA, Chess-Williams R, McDermott C. Novel insights into the mechanism of cyclophosphamide-induced bladder toxicity: chloroacetaldehyde's contribution to urothelial dysfunction in vitro. Arch Toxicol. 2019, 93:3291-303. 10.1007\/s00204-019-02589-1","journal-title":"Arch Toxicol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2570","article-title":"Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study","volume":"12","author":"Gor PP","year":"2010","unstructured":"Gor PP, Su HI, Gray RJ, et al.. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res. 2010, 12:R26. 10.1186\/bcr2570","journal-title":"Breast Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson PA","year":"2016","unstructured":"Thompson PA, Tam CS, O'Brien SM, et al.. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016, 127:303-9. 10.1182\/blood-2015-09-667675","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8345737","article-title":"Revisited cyclophosphamide in the treatment of lupus nephritis","volume":"2022","author":"Quan XY","year":"2022","unstructured":"Quan XY, Chen HT, Liang SQ, et al.. Revisited cyclophosphamide in the treatment of lupus nephritis. Biomed Res Int. 2022, 2022:8345737. 10.1155\/2022\/8345737","journal-title":"Biomed Res Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone JH","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al.. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010, 363:221-32. 10.1056\/NEJMoa0909905","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(71)92046-0","article-title":"Cyclophosphamide and human organ transplantation","volume":"2","author":"Starzl TE","year":"1971","unstructured":"Starzl TE, Halgrimson CG, Penn I, et al.. Cyclophosphamide and human organ transplantation. Lancet. 1971, 2:70-4. 10.1016\/s0140-6736(71)92046-0","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.08.014","article-title":"Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease","volume":"21","author":"Al-Homsi AS","year":"2015","unstructured":"Al-Homsi AS, Roy TS, Cole K, Feng Y, Duffner U. Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant. 2015, 21:604-11. 10.1016\/j.bbmt.2014.08.014","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2023.14.6.5","article-title":"Post-transplant cyclophosphamide for the prevention of graft-vs.-host disease in allogeneic hematopoietic cell transplantation: a guide to management for the advanced practitioner","volume":"14","author":"Kachur E","year":"2023","unstructured":"Kachur E, Patel JN, Morse AL, Moore DC, Arnall JR. Post-transplant cyclophosphamide for the prevention of graft-vs.-host disease in allogeneic hematopoietic cell transplantation: a guide to management for the advanced practitioner. J Adv Pract Oncol. 2023, 14:520-32. 10.6004\/jadpro.2023.14.6.5","journal-title":"J Adv Pract Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03817.x","article-title":"An overview of cyclophosphamide and ifosfamide pharmacology","volume":"17","author":"Fleming RA","year":"1997","unstructured":"Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 1997, 17:146S-54S. 10.1002\/j.1875-9114.1997.tb03817.x","journal-title":"Pharmacotherapy"},{"key":"ref11","article-title":"Cyclophosphamide and urinary bladder toxicity","volume":"21","author":"Philips FS","year":"1961","unstructured":"Philips FS, Sternberg SS, Cronin AP, Vidal PM. Cyclophosphamide and urinary bladder toxicity. Cancer Res. 1961, 21:1577-89.","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-91-2-221","article-title":"Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis","volume":"91","author":"Plotz PH","year":"1979","unstructured":"Plotz PH, Klippel JH, Decker JL, Grauman D, Wolff B, Brown BC, Rutt G. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med. 1979, 91:221-3. 10.7326\/0003-4819-91-2-221","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150065","article-title":"Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases","volume":"42","author":"Yilmaz N","year":"2015","unstructured":"Yilmaz N, Emmungil H, Gucenmez S, et al.. Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases. J Rheumatol. 2015, 42:1661-6. 10.3899\/jrheum.150065","journal-title":"J Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams C","year":"1996","unstructured":"Talar-Williams C, Hijazi YM, Walther MM, et al.. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996, 124:477-84. 10.7326\/0003-4819-124-5-199603010-00003","journal-title":"Ann Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6228","article-title":"Bladder carcinoma associated with cyclophosphamide therapy for ovarian cancer occurring with a latency of 20 years","volume":"82","author":"Volm T","year":"2001","unstructured":"Volm T, Pfaff P, Gnann R, Kreienberg R. Bladder carcinoma associated with cyclophosphamide therapy for ovarian cancer occurring with a latency of 20 years. Gynecol Oncol. 2001, 82:197-9. 10.1006\/gyno.2001.6228","journal-title":"Gynecol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/00365590701570953","article-title":"Urological implications of cyclophosphamide and ifosfamide","volume":"42","author":"Lawson M","year":"2008","unstructured":"Lawson M, Vasilaras A, De Vries A, Mactaggart P, Nicol D. Urological implications of cyclophosphamide and ifosfamide. Scand J Urol Nephrol. 2008, 42:309-17. 10.1080\/00365590701570953","journal-title":"Scand J Urol Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1594","article-title":"Ifosfamide-induced malignancy of ureter and bladder","volume":"9","author":"Sannu A","year":"2017","unstructured":"Sannu A, Radha R, Mathews A, Padmakumari Mony R, Prahladan A, James FV. Ifosfamide-induced malignancy of ureter and bladder. Cureus. 2017, 9:e1594. 10.7759\/cureus.1594","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000496331","article-title":"Severe hemorrhagic cystitis caused by cyclophosphamide and capecitabine therapy in breast cancer patients: two case reports and literature review","volume":"12","author":"Tanaka T","year":"2019","unstructured":"Tanaka T, Nakashima Y, Sasaki H, Masaki M, Mogi A, Tamura K, Takamatsu Y. Severe hemorrhagic cystitis caused by cyclophosphamide and capecitabine therapy in breast cancer patients: two case reports and literature review. Case Rep Oncol. 2019, 12:69-75. 10.1159\/000496331","journal-title":"Case Rep Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197102112840602","article-title":"Urinary-bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy","volume":"284","author":"Johnson WW","year":"1971","unstructured":"Johnson WW, Meadows DC. Urinary-bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy. N Engl J Med. 1971, 284:290-4. 10.1056\/NEJM197102112840602","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1128\/iai.38.2.558-562.1982","article-title":"Increased severity of urinary tract infection and bacteremia in mice with urinary bladder injury induced by cyclophosphamide","volume":"38","author":"Lyon D","year":"1982","unstructured":"Lyon D, Howard EB, Montgomerie JZ. Increased severity of urinary tract infection and bacteremia in mice with urinary bladder injury induced by cyclophosphamide. Infect Immun. 1982, 38:558-62. 10.1128\/iai.38.2.558-562.1982","journal-title":"Infect Immun"},{"key":"ref21","article-title":"Emphysematous cystitis: possible side-effect of cyclophosphamide therapy","volume":"50","author":"Abuzarad H","year":"1998","unstructured":"Abuzarad H, Gadallah MF, Rabb H, Vermess M, Ramirez G. Emphysematous cystitis: possible side-effect of cyclophosphamide therapy. Clin Nephrol. 1998, 50:394-6.","journal-title":"Clin Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18722","article-title":"Emphysematous cystitis in a patient receiving cyclophosphamide","volume":"13","author":"Al Zein S","year":"2021","unstructured":"Al Zein S. Emphysematous cystitis in a patient receiving cyclophosphamide. Cureus. 2021, 13:e18722. 10.7759\/cureus.18722","journal-title":"Cureus"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.632","article-title":"Incidence and nature of BK and adenovirus infections in post-transplant cyclophosphamide-based adult allogeneic hematopoietic cell transplant","volume":"30","author":"Dahi PB","year":"2024","unstructured":"Dahi PB, Li Y, Shaffer BC, et al.. Incidence and nature of BK and adenovirus infections in post-transplant cyclophosphamide-based adult allogeneic hematopoietic cell transplant. Transplant Cell Ther. 2024, 30:439. 10.1016\/j.jtct.2023.12.632","journal-title":"Transplant Cell Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfu233","article-title":"Molecular mechanisms of acrolein toxicity: relevance to human disease","volume":"143","author":"Moghe A","year":"2015","unstructured":"Moghe A, Ghare S, Lamoreau B, Mohammad M, Barve S, McClain C, Joshi-Barve S. Molecular mechanisms of acrolein toxicity: relevance to human disease. Toxicol Sci. 2015, 143:242-55. 10.1093\/toxsci\/kfu233","journal-title":"Toxicol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.5772\/50095","article-title":"Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS)","author":"Poluzzi E","year":"2012","unstructured":"Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). Karahoca A (ed): IntechOpen, London, UK; 2012. 10.5772\/50095"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1086\/599829","article-title":"Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study","volume":"49","author":"Cesaro S","year":"2009","unstructured":"Cesaro S, Hirsch HH, Faraci M, et al.. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect Dis. 2009, 49:233-40. 10.1086\/599829","journal-title":"Clin Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23247","article-title":"Low incidence of adenovirus hemorrhagic cystitis following autologous hematopoietic stem cell transplantation in the rituximab era","volume":"87","author":"Mori Y","year":"2012","unstructured":"Mori Y, Miyamoto T, Kamezaki K, et al.. Low incidence of adenovirus hemorrhagic cystitis following autologous hematopoietic stem cell transplantation in the rituximab era. Am J Hematol. 2012, 87:828-30. 10.1002\/ajh.23247","journal-title":"Am J Hematol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2015.11929318","article-title":"Late presentation of adenovirus-induced hemorrhagic cystitis and ureteral obstruction in a kidney-pancreas transplant recipient","volume":"28","author":"Klein J","year":"2015","unstructured":"Klein J, Kuperman M, Haley C, et al.. Late presentation of adenovirus-induced hemorrhagic cystitis and ureteral obstruction in a kidney-pancreas transplant recipient. Proc (Bayl Univ Med Cent). 2015, 28:488-91. 10.1080\/08998280.2015.11929318","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2016.07.030","article-title":"Review of advances in uroprotective agents for cyclophosphamide- and ifosfamide-induced hemorrhagic cystitis","volume":"100","author":"Matz EL","year":"2017","unstructured":"Matz EL, Hsieh MH. Review of advances in uroprotective agents for cyclophosphamide- and ifosfamide-induced hemorrhagic cystitis. Urology. 2017, 100:16-9. 10.1016\/j.urology.2016.07.030","journal-title":"Urology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/320672-urotoxicity-of-cyclophosphamide-a-comparison-across-neoplastic-autoimmune-and-transplant-indications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T22:34:51Z","timestamp":1733438091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/320672-urotoxicity-of-cyclophosphamide-a-comparison-across-neoplastic-autoimmune-and-transplant-indications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.75180","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}